Dermatology

AbbVie Patents Are Costly for Healthcare Consumers

April 11th 2020

By Tony Hagen

Article

The Danish medical system saved 82.8% on adalimumab by switching almost all patients from the reference product to biosimilars, but such a benefit for the US healthcare system may not be possible, according to a new study.

BiosanaPharma Reports Positive Phase 1 Results for Omalizumab Biosimilar

April 9th 2020

By Tony Hagen

Article

With positive phase 1 study results and a manufacturing process that may cut costs significantly, BiosanaPharma hopes its omalizumab biosimilar candidate will have an edge on the worldwide market.

NeuClone Completes Early Testing for Psoriasis Biosimilar

April 8th 2020

By The Center for Biosimilars

Article

NeuClone said phase 1 patient monitoring and blood sampling has been completed for its ustekinumab biosimilar candidate, which is targeted at the $6.6 billion in annual revenue earned by Stelara, a Janssen Pharmaceutical Companies product.

Alvotech Hf and DKSH Announce Plans to Bring an Adalimumab Biosimilar to Market

March 26th 2020

By The Center for Biosimilars

Article

Alvotech Hf and DSH hope to get an adalimumab biosimilar approved in the United States, Europe, and selected Southeast Asia markets.

Study: Adalimumab Plus Hydroxychloroquine Leads to Hair Regrowth in Lichen Planopilaris

February 27th 2020

By Skylar Jeremias

Article

Lichen planopilaris (LPP) is a type of scarring hair loss that occurs when lichen plaus, a relatively common inflammatory skin disease, affects areas of skin where hair grows. It destroys the hair follicle and replaces it with scarring, resulting in permanent hair loss. LPP’s causes and pathology are unknown.

2019 Saw Mounting Evidence to Support Nonmedical Switching, Review Article Says

February 21st 2020

By Deana Ferreri, PhD

Article

A recent year-in-review article outlines studies published in 2019 about nonmedical switching from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

AbbVie: Next-Generation Skyrizi and Rinvoq Are Showing Traction in Humira Space

February 21st 2020

By Skylar Jeremias

Article

Pharmaceutical giant AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira (adalimumab) sales decline and more biosimilars to the blockbuster arthritis drug enter the market.

No Higher Risk of Cancer for Patients With Psoriasis Treated With Biologics, Analysis Finds

February 19th 2020

By The Center for Biosimilars Staff

Article

The review found no increased risk of cancer when looking at both keratinocyte cancer and lymphomas in patients on biologics vs conventional therapy. Overall, however, patients with psoriasis appear to have a slightly increased risk of certain cancers.

Animal Study of Secukinumab Biosimilar Gene Therapy Yields Promising Results

January 25th 2020

By Deana Ferreri, PhD

Article

The study examined secukinumab biosimilar lentivirus-based gene therapy, which showed successful and prolonged expression of the recombinant antibody in rats.

Canadian Organizations Gather Stakeholders to Stimulate Biosimilar Acceptance

December 18th 2019

By The Center for Biosimilars Staff

Article

The pan-Canadian Pharmaceutical Alliance engaged the Canadian Agency for Drugs and Technologies in Health to lead a multiphase stakeholder consultation process to encourage biosimilar uptake.